Cardiotrack, a disruptive healthcare diagnostics solution that is making healthcare delivery more efficient has secured $2 Million in Pre series A funding round led by angel investor Girish Narasimhan, Managing Director & Principal, Corporate Finance Associates Worldwide Inc.
Read also – Aramco Completes Acquisition of Esmax
Seasoned professional and co-investor Y S Shashidhar, Advisor, Dubai Holdings LLC (& former Partner & Managing Director at Frost & Sullivan for Middle East, Africa and South Asia Region) also join the funding round.
Read also – wagely Secures US$23M in New Funding
Commenting on the funding, Avin Agarwal, Founder & CEO, Cardiotrack, said, “We are thrilled to have secured this investment as we continue to innovate and expand our reach in our mission to drive positive change in the healthcare industry. The investment further validates the venture’s direction and the immense value it brings in improving the healthcare experience for both providers and consumers.”
Girish Narasimhan, seasoned angel investor, Member of the Board, Cardiotrack, said, “Avin and the team are deeply committed to their mission to revolutionise healthcare screening. They also have a strong market validation by having many leading life & health insurance providers as their clients. We strongly believe the venture will rightfully cement its place among start-ups that are reshaping the future of healthcare.”
About Cardiotrack
Founded in 2014, Cardiotrack is a multiple parameter handheld diagnostic device including 12-lead ECG monitor, pulse oximeter and blood pressure monitor integrated with mobile-based practice management solution and cloud backend. Low cost, portability and network-connectivity mean that Cardiotrack may be deployed at the primary care level and the resultant scan of the patient can be delivered instantaneously to a specialist anywhere in the world.
